Affiliations: Department Of Clinical Medicine, University of Rome La
Sapienza, Rome, Italy
Note: [] Correspondence: Isabella Quinti, Department of Clinical
Medicine, University of Rome La Sapienza, Rome, Italy. Tel.: +39 06 49972007;
Fax: +39 06 4463877; E-mail: [email protected]
Abstract: Medical knowledge on the clinical investigation of human normal
immunoglobulin for intravenous administration and treatment regimens are in a
state of continuous development. Due to recent achievements, the question
arises whether the currently established indications and their respective
posologies might require modification to more adequately reflect current
clinical practice with intravenous or subcutaneous immunoglobulins as
substitutive therapy in patients affected by primary and secondary
immunodeficiencies and as immunomodulators in patients affected by autoimmune
disorders. In addition, immunoglobulin therapies used "off label" have proved
beneficial and other possible inclusion will be expected in the next future. In
this review we will identify the clinical and immunological benefits and limits
of imunoglobulin treatments and outline the physician's persepective on this
topic.